Cytek Biosciences, Inc. (CTKB)

NASDAQ: CTKB · Real-Time Price · USD
2.770
+0.180 (6.95%)
At close: May 30, 2025, 4:00 PM
2.710
-0.060 (-2.17%)
After-hours: May 30, 2025, 6:30 PM EDT
6.95%
Market Cap 350.85M
Revenue (ttm) 197.05M
Net Income (ttm) -11.25M
Shares Out 126.66M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE 110.80
Dividend n/a
Ex-Dividend Date n/a
Volume 1,565,214
Open 2.570
Previous Close 2.590
Day's Range 2.540 - 2.820
52-Week Range 2.370 - 7.630
Beta 1.42
Analysts Hold
Price Target 6.00 (+116.61%)
Earnings Date May 8, 2025

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. The company offers aurora and northern lights systems delivers cell analysis; aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; enhanced small particle detection; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent c... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jul 23, 2021
Employees 648
Stock Exchange NASDAQ
Ticker Symbol CTKB
Full Company Profile

Financial Performance

In 2024, Cytek Biosciences's revenue was $200.45 million, an increase of 3.85% compared to the previous year's $193.02 million. Losses were -$6.02 million, -50.44% less than in 2023.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for CTKB stock is "Hold." The 12-month stock price forecast is $6.0, which is an increase of 116.61% from the latest price.

Price Target
$6.0
(116.61% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

Cytek has announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system.

2 days ago - GlobeNewsWire

Cytek Biosciences to participate at the Goldman Sachs 46th Annual Global Healthcare Conference

FREMONT, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming G...

3 days ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participa...

20 days ago - Seeking Alpha

Cytek Biosciences Reports First Quarter 2025 Financial Results

FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results ...

23 days ago - GlobeNewsWire

Cytek Biosciences: With Growth, Low Debt, And A Positive Long-Term Outlook, Is It Undervalued?

The relative valuations conducted in this article suggest that Cytek presents an undervaluation in the range of 16.43% to 109.37%. Cytek has reported net losses due to its growth strategy. In fact, in...

27 days ago - Seeking Alpha

Cytek® Biosciences Brings Cutting-Edge Cell Analysis Solutions to CYTO and IMMUNOLOGY2025

Cytek Biosciences is showcasing its patented Full Spectrum Profiling™ technology at CYTO 2025 & American Association of Immunologists' (AAI) IMMUNOLOGY2025

4 weeks ago - GlobeNewsWire

Why Cytek Biosciences Should Beat Q1 Earnings Expectations

There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitabi...

4 weeks ago - Seeking Alpha

Cytek Biosciences to Report First Quarter 2025 Financial Results on May 8, 2025

FREMONT, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the first quarter 2025...

5 weeks ago - GlobeNewsWire

Cytek® Biosciences Expands Cell Analysis Offerings with the Affordable, User-Friendly Cytek® Muse® Micro System

FREMONT, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Today, Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that it has added transformative capabilities to its iconic Cytek® Guava® Muse® cell analyze...

2 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Par...

3 months ago - Seeking Alpha

Cytek Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Outlook

FREMONT, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results...

3 months ago - GlobeNewsWire

Cytek Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and ...

3 months ago - GlobeNewsWire

Cytek Biosciences to Participate in Upcoming Investor Conferences

FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following...

4 months ago - GlobeNewsWire

Upgrading Cytek Biosciences Stock On An Upcoming Catalyst

I'm upgrading Cytek Biosciences from "Hold" to "Buy" due to improving financials, expanding installed base, and strong demand for Aurora and Northern Lights systems. Cytek's Q3 FY2024 revenue up 7% Yo...

5 months ago - Seeking Alpha

Cytek Biosciences to present at the 43rd Annual J.P. Morgan Healthcare Conference

FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...

5 months ago - GlobeNewsWire

Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025

FREMONT, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Board of Directors has approved a stock r...

5 months ago - GlobeNewsWire

Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference

FREMONT, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming ...

6 months ago - GlobeNewsWire

Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program

FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Brea...

6 months ago - GlobeNewsWire

Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter

FREMONT, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) has introduced an Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system.

7 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q3 2024 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer Willia...

7 months ago - Seeking Alpha

Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe

FREMONT, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) is set to elevate its presence at this year's premier clinical industry events across the globe.

9 months ago - GlobeNewsWire

Cytek Announces Resignation of Chief Operating Officer Chris Williams

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams,...

9 months ago - GlobeNewsWire

Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility

FREMONT, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its San Diego reagent manufacturing facility has been awarded EN ISO 13485:2016 Quality M...

10 months ago - GlobeNewsWire

Cytek Biosciences, Inc. (CTKB) Q2 2024 Earnings Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William ...

10 months ago - Seeking Alpha

Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm

Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.

10 months ago - GlobeNewsWire